Sulforaphane (Synonyms: 萝卜硫素)

目录号: HY-13755 纯度: 98.87%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Sulforaphane 是一种具有口服活性的 Keap1/Nrf2/ARE 诱导剂。Sulforaphane 能促进肿瘤抑制蛋白的转录，并有效地抑制 HDACs 的活性。Sulforaphane 通过激活 Keap1/Nrf2/ARE 途径，以及进一步诱导 HO-1 的表达保护心脏。Sulforaphane 通过 AMPK 依赖性信号传导抑制高糖诱导的胰腺癌。Sulforaphane 具有抗癌和抗炎活性。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Sulforaphane Chemical Structure

CAS No. : 4478-93-7

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
5 mg	￥375	In-stock
10 mg	￥600	In-stock
25 mg	￥1350	In-stock
50 mg	￥2500	In-stock
100 mg	￥4500	In-stock
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Sulforaphane:

(R)-Sulforaphane In-stock

MCE 顾客使用本产品发表的 45 篇科研文献

: Sulforaphane purchased from MCE. Usage Cited in: Eur J Pharmacol. 2021 Aug 7;174412. [Abstract]; Western blotting analysis shows that CIBP can significantly induce the protein expression of Nrf2 and HO-1 in the spinal cord and that intrathecal administration of Sulforaphane (SFN) can further promoted the protein expression of Nrf2 and HO-1 protein.

: Sulforaphane purchased from MCE. Usage Cited in: Eur J Pharmacol. 2021 Aug 7;174412. [Abstract]; Immunofluorescence histochemistry confirmes that Sulforaphane (SFN) treatment further increased Nrf2 and HO-1 expression in the dorsal horn of the spinal cord of CIBP rats.

: Sulforaphane purchased from MCE. Usage Cited in: Theranostics. 2020 Jun 5;10(16):7319-7334. [Abstract]; Western blot detection of Nrf2, TLR4, IRF1, iNOS, and ARG-1 levels following Sulforaphane (SFN; 10 μM or 20 μM) treatment or Nrf2 upregulation/downregulation in BMDMs co-cultured with COM-stimulated TECs. SFN treatment activates Nrf2 expression, which then downregulates the expression of TLR4, IRF1, and iNOS and upregulates the expression of ARG-1.

: Sulforaphane purchased from MCE. Usage Cited in: Theranostics. 2020 Jun 5;10(16):7319-7334. [Abstract]; The distribution of iNOS (green) and ARG-1 (red) in BMDMs according to immunofluorescence. Sulforaphane (SFN; 10 μM or 20 μM) decreases iNOS and increases ARG-1 levels.

: Sulforaphane purchased from MCE. Usage Cited in: Vascul Pharmacol. 2018 Oct;109:56-71. [Abstract]; A representative western blot analysis gel showing the reduces abundance of eNOS relative to GAPDH in tissues cultured under hyperglycaemic conditions (25 mM glucose: 25) versus either freshly isolated tissues (F, first lane on left) or tissues cultured under euglycaemic conditions (10 mM glucose: 10). The abundance of eNOS is preserved for tissues cultured in 25 mM glucose along with 1 μM Sulforaphane (25+S).

Sulforaphane 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 HDAC 亚型特异性产品:

查看所有亚型

HDAC HDAC1 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HDAC10 HDAC11 HD1 HD2

查看 Bcl-2 Family 亚型特异性产品:

查看所有亚型

Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim

查看 Caspase 亚型特异性产品:

查看所有亚型

Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

生物活性
纯度 & 产品资料
参考文献

生物活性

Sulforaphane is an orally active inducer of the Keap1/Nrf2/ARE pathway. Sulforaphane promotes the transcription of tumor-suppressing proteins and effectively inhibits the activity of HDACs. Through the activation of the Keap1/Nrf2/ARE pathway and further induction of HO-1 expression, Sulforaphane protects the heart. Sulforaphane suppresses high glucose-induced pancreatic cancer through AMPK-dependent signal transmission. Sulforaphane exhibits both anticancer and anti-inflammatory properties^[1]^[2]^[3]^[4]^[5]^[6].

IC₅₀ & Target^[1]

HDAC

Bax

Caspase-3

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A-375	IC₅₀	24.52 μM Compound: SFA	Antiproliferative activity against human A375 cells after 72 hrs by CCK8 assay Antiproliferative activity against human A375 cells after 72 hrs by CCK8 assay	[PMID: 30282324]
A-431	IC₅₀	15.76 μM Compound: SFN	Antiproliferative activity against human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27135370]
A-431	IC₅₀	9 μM Compound: SFN	Inhibition of EGFR-TK in human A431 cell lysate assessed as reduction in EGF stimulated kinase activity after 60 mins using biotinylated peptide substrate by ELISA Inhibition of EGFR-TK in human A431 cell lysate assessed as reduction in EGF stimulated kinase activity after 60 mins using biotinylated peptide substrate by ELISA	[PMID: 27135370]
A549	IC₅₀	> 10 μM Compound: SFN	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
A549	IC₅₀	11.93 μM Compound: SFA	Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay	[PMID: 30282324]
A549	IC₅₀	20.18 μM Compound: SFN	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
A549	IC₅₀	21.99 μM Compound: 77, SFN	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 23685571]
AGS	IC₅₀	18.41 μM Compound: SFN	Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
ARPE-19	IC₅₀	10 μM Compound: Sulforaphane	Cytotoxicity against human ARPE-19 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human ARPE-19 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35549469]
Caco-2	IC₅₀	79.83 μM Compound: SF, Sulforaphane	Cytotoxicity against human Caco2 cells incubated for 24 hrs by WST1 dye reduction assay Cytotoxicity against human Caco2 cells incubated for 24 hrs by WST1 dye reduction assay	[PMID: 22998472]
CCRF-CEM	IC₅₀	> 10 μM Compound: SFN	Antiproliferative activity against human CCRF-CEM cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human CCRF-CEM cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
DU-145	IC₅₀	10 μM Compound: 1	Antiproliferative activity against human DU145 cells assessed as viable cells after 24 hrs Antiproliferative activity against human DU145 cells assessed as viable cells after 24 hrs	[PMID: 18855447]
DU-145	IC₅₀	13.8 μM Compound: SF, Sulforaphane	Cytotoxicity against human DU145 cells incubated for 24 hrs by WST1 dye reduction assay Cytotoxicity against human DU145 cells incubated for 24 hrs by WST1 dye reduction assay	[PMID: 22998472]
HCC827	IC₅₀	> 10 μM Compound: SFN	Antiproliferative activity against human HCC827 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human HCC827 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
HCT-116	IC₅₀	11.59 μM Compound: 77, SFN	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 23685571]
HCT-116	IC₅₀	36.73 μM Compound: SFA	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HCT116 cells after 72 hrs by CCK8 assay	[PMID: 30282324]
HeLa	IC₅₀	> 10 μM Compound: SFN	Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
HeLa	IC₅₀	66.09 μM Compound: SFA	Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay	[PMID: 30282324]
Hep 3B2	IC₅₀	> 10 μM Compound: SFN	Antiproliferative activity against human Hep3B cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human Hep3B cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
HepG2	EC₅₀	1.2 μM Compound: Sulforaphane	Activation of Nrf2 (unknown origin) expressed in human HepG2 cells after 5 hrs by ARE-driven luciferase reporter gene assay Activation of Nrf2 (unknown origin) expressed in human HepG2 cells after 5 hrs by ARE-driven luciferase reporter gene assay	[PMID: 28126440]
HepG2	IC₅₀	14.05 μM Compound: 77, SFN	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 23685571]
HepG2	IC₅₀	20.99 μM Compound: SFN	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
HepG2	IC₅₀	24.89 μM Compound: SF, Sulforaphane	Cytotoxicity against human HepG2 cells incubated for 24 hrs by WST1 dye reduction assay Cytotoxicity against human HepG2 cells incubated for 24 hrs by WST1 dye reduction assay	[PMID: 22998472]
HepG2	EC₅₀	4 μM Compound: sulforaphane	Induction of ARE in human HepG2 cells by luciferase assay Induction of ARE in human HepG2 cells by luciferase assay	[PMID: 16562850]
HepG2	IC₅₀	8.357 μM Compound: SFN	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
HONE1 cell line	IC₅₀	19.26 μM Compound: SFN	Antiproliferative activity against human HONE1 cell line assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human HONE1 cell line assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
Jurkat	IC₅₀	> 10 μM Compound: SFN	Antiproliferative activity against human Jurkat cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human Jurkat cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
Jurkat	IC₅₀	15 μM Compound: SFN	Cytotoxicity against human Jurkat T cells assessed as decrease in cell viability after 24 hrs by flow cytometric analysis Cytotoxicity against human Jurkat T cells assessed as decrease in cell viability after 24 hrs by flow cytometric analysis	[PMID: 22200402]
Jurkat	IC₅₀	3.8 μM Compound: 1	Antiproliferative activity against human lymphoblastoid cells using annexin-V FITC and PI staining by flow cytometry Antiproliferative activity against human lymphoblastoid cells using annexin-V FITC and PI staining by flow cytometry	[PMID: 18855447]
LoVo	IC₅₀	18.52 μM Compound: SFN	Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
LoVo	IC₅₀	22.9 μM Compound: SFN	Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay	[PMID: 29945793]
LoVo	IC₅₀	22.9 μM Compound: SFN	Cytotoxicity against human LoVo cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human LoVo cells after 72 hrs by sulforhodamine B assay	[PMID: 28342398]
MCF7	IC₅₀	> 10 μM Compound: SFN	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
MCF7	IC₅₀	17.66 μM Compound: 77, SFN	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 23685571]
MCF7	IC₅₀	23.13 μM Compound: SFN	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
MDA-MB-231	IC₅₀	> 10 μM Compound: SFN	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
MDA-MB-231	IC₅₀	22.18 μM Compound: SFN	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
NCI-H1299	IC₅₀	11.57 μM Compound: SFN	Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
NCI-H1299	IC₅₀	7.648 μM Compound: SFN	Antiproliferative activity against human H1299 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human H1299 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
NCI-H1650	IC₅₀	22.01 μM Compound: SFN	Antiproliferative activity against human NCI-H1650 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1650 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
NCI-H1975	IC₅₀	> 10 μM Compound: SFN	Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
NCI-H460	IC₅₀	21.25 μM Compound: SFN	Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
OVCAR-3	IC₅₀	18.44 μM Compound: SFN	Antiproliferative activity against human OVCAR-3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human OVCAR-3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
PC-3	IC₅₀	32.38 μM Compound: SF, Sulforaphane	Cytotoxicity against human PC3 cells incubated for 24 hrs by WST1 dye reduction assay Cytotoxicity against human PC3 cells incubated for 24 hrs by WST1 dye reduction assay	[PMID: 22998472]
PC-9	IC₅₀	6.308 μM Compound: SFN	Antiproliferative activity against human PC9 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human PC9 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
Peritoneal macrophage	CC₅₀	> 10 μM Compound: SFN	Cytotoxicity against mouse peritoneal macrophages assessed as reduction in cell viability measured after 24 hrs by CCK8 assay Cytotoxicity against mouse peritoneal macrophages assessed as reduction in cell viability measured after 24 hrs by CCK8 assay	[PMID: 34119834]
RAW264.7	IC₅₀	400 nM Compound: sulforaphane	Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production after 48 hrs by Griess assay Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production after 48 hrs by Griess assay	[PMID: 25965897]
SGC-7901	IC₅₀	24.95 μM Compound: SFN	Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
SH-SY5Y	IC₅₀	13.27 μM Compound: 77, SFN	Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay	[PMID: 23685571]
SH-SY5Y	IC₅₀	20 μM Compound: sulforaphane	Cytotoxicity against human SH-SY5Y cells after 24 hrs by Annexin V-PE-based flow cytometry Cytotoxicity against human SH-SY5Y cells after 24 hrs by Annexin V-PE-based flow cytometry	[PMID: 24140951]
SiHa	IC₅₀	9.953 μM Compound: SFN	Antiproliferative activity against human SiHa cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human SiHa cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
SMMC-7721	IC₅₀	7.87 μM Compound: SFA	Antiproliferative activity against human SMMC7721 cells after 72 hrs by CCK8 assay Antiproliferative activity against human SMMC7721 cells after 72 hrs by CCK8 assay	[PMID: 30282324]
SW480	IC₅₀	17.84 μM Compound: SFN	Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
U-251	IC₅₀	22.47 μM Compound: SFN	Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
U2OS	EC₅₀	0.58 μM Compound: SFN	Activation of ED-tagged Nrf2 in human U2OS cells co-expressing Keap1 assessed as induction of NRF2 translocation to nucleus after 6 hrs by beta-galactosidase based chemiluminescent assay Activation of ED-tagged Nrf2 in human U2OS cells co-expressing Keap1 assessed as induction of NRF2 translocation to nucleus after 6 hrs by beta-galactosidase based chemiluminescent assay	[PMID: 31312409]
U2OS	EC₅₀	0.58 μM Compound: SFN	Activation of NRF2 in human U2OS cells co-expressing Keap1 assessed as induction of NRF2 translocation to nucleus after 6 hrs by beta-galactosidase based chemiluminescent assay Activation of NRF2 in human U2OS cells co-expressing Keap1 assessed as induction of NRF2 translocation to nucleus after 6 hrs by beta-galactosidase based chemiluminescent assay	[PMID: 30540174]
U2OS	EC₅₀	0.87 μM Compound: SFN	Activation of NRF2 in human U2OS cells co-expressing Keap1 (unknown origin) assessed as induction of NRF2 translocation to nucleus incubated for 6 hrs by beta-galactosidase based chemiluminescent assay Activation of NRF2 in human U2OS cells co-expressing Keap1 (unknown origin) assessed as induction of NRF2 translocation to nucleus incubated for 6 hrs by beta-galactosidase based chemiluminescent assay	[PMID: 31670201]
U-937	IC₅₀	> 10 μM Compound: SFN	Antiproliferative activity against human U937 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human U937 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
Vero	IC₅₀	13.72 μM Compound: 77, SFN	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay	[PMID: 23685571]

体外研究
(In Vitro)

Sulforaphane (0-30 μM) 以剂量依赖性方式引发细胞周期停滞和细胞凋亡 (apoptosis)。这种由 Sulforaphane 诱导的细胞周期停滞与细胞周期蛋白 A 和 B1 的表达增加有关^[1]。
Sulforaphane (0-30 μM) 能抑制 HT29 细胞的生长再启动，降低细胞活性，对分化的细胞具有较低的毒性^[1]。
Sulforaphane (10 μM, 24 小时) 预处理 H9c2 细胞后，可以减少凋亡细胞数量，降低促凋亡蛋白 (Bax、caspase-3、细胞色素 c) 的表达，并抵消 Doxorubicin (HY-15142A) (1 μM, 2 小时) 引发的线粒体膜电位增加^[2]。
Sulforaphane (10 μM, 2 或 24 小时) 通过激活 Keap1/Nrf2/ARE 途径，以及进一步诱导 HO-1 的表达，能有效地减少 Doxorubicin (1 μM, 2 或 24 小时) 诱导的 H9c2 细胞中 ROS 的产生和细胞凋亡^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:	H9c2 cells
Concentration:	Sulforaphane: 10 μM; Doxorubicin: 1 μM
Incubation Time:	Sulforaphane: 2h; Doxorubicin: 2, 24h
Result:	Prevented the release of cytochrome c into the cytosol. Prevented the translocation of Bax into the cytosol. Attenuated the doxorubicin-induced increase in the levels of cleaved caspase-3. Induced a significant increase in HO-1 protein expression. Induced a significantly higher level of Nrf2 expression in the nucleus compared to the cytoplasm.

Apoptosis Analysis^[2]

Cell Line:	H9c2 cells
Concentration:	Sulforaphane: 10 μM; Doxorubicin: 1 μM
Incubation Time:	Sulforaphane: 2h; Doxorubicin: 24h
Result:	Protected the H9c2 cells against doxorubicin-induced cell death. Increased cell viability in a dose-dependent manner. Significantly reduced the number of apoptotic cells treated with Doxorubicin.

RT-PCR^[2]

Cell Line:	H9c2 cells
Concentration:	Sulforaphane: 10 μM; Doxorubicin: 1 μM
Incubation Time:	Sulforaphane: 2, 24h; Doxorubicin: 2, 24h
Result:	Induced heme oxygenase-1 (HO-1) mRNA expression in a dose-dependent manner.

体内研究
(In Vivo)

Sulforaphane (13.3, 17.7, 26.6 mg/kg; 灌胃; 5 天) 能抑制雌性 Sprague-Dawley 大鼠接受 DMBA (HY-W011845) (8 mg/mL) 单次剂量处理后乳腺肿瘤的形成^[3]。
Sulforaphane (13.3, 26.6 mg/kg; 灌胃; 5 天) 能减少由 DMBA (8 mg/mL) 在雌性 Sprague-Dawley 大鼠中诱发的乳腺肿瘤的发生率、多发性和重量，并延迟其发展^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Sprague-Dawley rat^[3]
Dosage:	Sulforaphane: 13.3, 17.7, 26.6 mg/kg; DMBA (HY-W011845): 8 mg/mL
Administration:	Oral gavage; 5 days
Result:	Prevented the occurrence of tumors in a dose-dependent manner. Significantly reduced the incidence of tumors.

Clinical Trial

分子量

177.29

Formula

C₆H₁₁NOS₂

CAS 号

4478-93-7

性状

液体（密度：1.17±0.1 g/cm³）

颜色

Colorless to light yellow

中文名称

萝卜硫素；莱菔硫烷

结构分类

Others

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-20°C, sealed storage, away from moisture and light

*该产品在溶液状态不稳定，建议您现用现配，即刻使用。

溶解性数据

细胞实验：

DMSO 中的溶解度 : ≥ 62.5 mg/mL (352.53 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	5.6405 mL	28.2024 mL	56.4048 mL
5 mM	1.1281 mL	5.6405 mL	11.2810 mL
10 mM	0.5640 mL	2.8202 mL	5.6405 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现用现配，即刻使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (14.10 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (14.10 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (14.10 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： 50% PEG300 50% Saline
Solubility: ≥ 50 mg/mL (282.02 mM); 澄清溶液
方案二

请依序添加每种溶剂： 0.5% CMC-Na/saline water
Solubility: ≥ 50 mg/mL (282.02 mM); 澄清溶液
方案三

请依序添加每种溶剂： 30% SBE-β-CD in Saline
Solubility: 10 mg/mL (56.40 mM); 澄清溶液; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

*该产品在溶液状态不稳定，建议您现用现配，即刻使用。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.75%

选择批次：

Data Sheet (647 KB) SDS (421 KB)

COA (190 KB) HNMR (191 KB) LCMS (139 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Gamet-Payrastre L, et al. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res. 2000 Mar 1;60(5):1426-33. [Content Brief]

[2]. Li B, et al. Sulforaphane prevents doxorubicin-induced oxidative stress and cell death in rat H9c2 cells. Int J Mol Med. 2015 Jul;36(1):53-64. [Content Brief]

[3]. Zhang Y, et al. Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornylisothiocyanates. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3147-50. [Content Brief]

[4]. Chen X, et al. Activation of Nrf2 by Sulforaphane Inhibits High Glucose-Induced Progression of PancreaticCancer via AMPK Dependent Signaling. ell Physiol Biochem. 2018;50(3):1201-1215. [Content Brief]

[5]. De Nicola GR, et al. Novel gram-scale production of enantiopure R-sulforaphane from Tuscan black kale seeds. Molecules. 2014 May 27;19(6):6975-86. [Content Brief]

[6]. Abdull Razis AF, et al. The natural chemopreventive phytochemical R-sulforaphane is a far more potent inducer of the carcinogen-detoxifying enzyme systems in rat liver and lung than the S-isomer. Int J Cancer. 2011 Jun 15;128(12):2775-82. [Content Brief]

Sulforaphane 相关分类

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现用现配，即刻使用。

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	5.6405 mL	28.2024 mL	56.4048 mL	141.0119 mL
	5 mM	1.1281 mL	5.6405 mL	11.2810 mL	28.2024 mL
	10 mM	0.5640 mL	2.8202 mL	5.6405 mL	14.1012 mL
	15 mM	0.3760 mL	1.8802 mL	3.7603 mL	9.4008 mL
	20 mM	0.2820 mL	1.4101 mL	2.8202 mL	7.0506 mL
	25 mM	0.2256 mL	1.1281 mL	2.2562 mL	5.6405 mL
	30 mM	0.1880 mL	0.9401 mL	1.8802 mL	4.7004 mL
	40 mM	0.1410 mL	0.7051 mL	1.4101 mL	3.5253 mL
	50 mM	0.1128 mL	0.5640 mL	1.1281 mL	2.8202 mL
	60 mM	0.0940 mL	0.4700 mL	0.9401 mL	2.3502 mL
	80 mM	0.0705 mL	0.3525 mL	0.7051 mL	1.7626 mL
	100 mM	0.0564 mL	0.2820 mL	0.5640 mL	1.4101 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

Sulforaphane (Synonyms: 萝卜硫素)

Customer Review

Other Forms of Sulforaphane:

MCE 顾客使用本产品发表的 45 篇科研文献

Sulforaphane 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 HDAC 亚型特异性产品:

查看 Bcl-2 Family 亚型特异性产品:

查看 Caspase 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Sulforaphane 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Sulforaphane (Synonyms: 萝卜硫素)

Customer Review

Other Forms of Sulforaphane:

Sulforaphane 相关抗体

MCE 顾客使用本产品发表的 45 篇科研文献

Sulforaphane 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 HDAC 亚型特异性产品:

查看 Bcl-2 Family 亚型特异性产品:

查看 Caspase 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Sulforaphane 相关抗体:

摩尔计算器

稀释计算器

Sulforaphane 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z